Events

Virtual AI Summit w/ Kevin Garwood and Peju Oshisanya

Panel Discussion: AI x Policy: Driving Responsible and Scalable Data Governance Best Practice – Looking Ahead at How External Stakeholders and Governmental Regulations Will Influence Data Strategy

  • Multinational companies – transferring and accessing data across borders, given different jurisdictions/laws/regulations
  • Brexit and the future of GDPR
  • European Union/US/China – what’s next in tech policy? How will it change tech investment and innovation? What does it mean for private companies?
  • Data Diversity
Speakers
  • Richard Self - Senior Lecturer in Governance of Advanced and Emerging Technologies, University of Derby
  • Eline Chivot - Senior Policy Analyst, Center for Data Innovation
  • Edwina Dunn - Co-Founder & Board Member, dunnhumby & Centre for Data Ethics & Innovation
  • Peju Oshisanya - Director – Clinical Programme Leader, Benevolent AI
  • Mike Wiley - Application CTO and VP Engineering, F5

Healthcare Track: Data Diversity Effort at BenevolentAI

→ Register here


Peju Oshisanya
AI Ethics, Data Diversity Advocate, Clinical Drug Development Leader at BenevolentAI

Peju is an innovative operational strategy expert with over 15 years wide-ranging experience relating to strategic programme leadership, planning and management of clinical trials with responsibility for global clinical programmes. She has extensive experience in working in early drug discovery and exploratory phases focused on the transition of early stage assets to clinical development. She has held leadership positions in programme management responsible for key clinical programmes and assets within Eli Lilly, Sanofi Aventis, Pfizer and Takeda. In her current role at BenevolentAI, she is responsible for driving the asset strategy to maximise the value of both early and late phase drug development programmes.

Kevin Garwood
Patient Data Manager at BenevolentAI

Kevin is a patient data manager for precision medicine activities at BenevolentAI and is responsible for managing information governance concerns for patient-level data and in identifying and acquiring clinical and –omic data sources that would support our drug discovery programmes. Kevin’s interests include bioethics, intellectual property law and better understanding the value chain that shapes the worth and applicability of health data in the field of precision medicine. Most of his work involves coordinating with stakeholders from very different parts of the company.


More Posts

You Might Also Like

Blog
AI in Drug Discovery
This blog seeks to demystify the application of artificial intelligence (AI) and machine learning (ML) in drug discovery by exploring some of the challenges, opportunities and progress that has been achieved in the field so far.
Jul 13, 2021
News
BenevolentAI announces the appointment of biopharma luminary Dr François Nader as Chairman
Dr Nader joins BenevolentAI as it embarks on ambitious growth plans to scale its AI platform, partnerships and drug portfolio.
Jul 9, 2021
Blog
Product design in AI-drug discovery: how to design products for and with scientific users
User interfaces can help drug discovery scientists to leverage insights from AI algorithms. Yet, designing products to enable scientific discovery is complex. Our product designer, Róża explores the key steps in her design process.
Jul 6, 2021
News
Baricitinib, first identified by BenevolentAI as a COVID-19 treatment, is granted emergency use in India in response to its escalating crisis
Baricitinib - first identified by BenevolentAI as a potential COVID-19 treatment - is accelerated for use in hospitalised patients in India following a continued surge in cases and fatalities.
May 5, 2021
Video
A New Era in Target Discovery: Collaborating with AstraZeneca on CKD and IPF
Finding the right target underpins the success of the entire drug discovery process. Learn how BenevolentAI’s collaboration with AstraZeneca is making a difference in CKD and IPF.
Apr 23, 2021
News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021